×
Exscientia Total Long Term Liabilities 2021-2024 | EXAI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Exscientia total long term liabilities from 2021 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
View More
Exscientia Total Long Term Liabilities 2021-2024 | EXAI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Exscientia total long term liabilities from 2021 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$76.9B
Takeda Pharmaceutical (TAK)
$43.9B
Merck (MKKGY)
$20.8B
Astellas Pharma (ALPMY)
$20.2B
Sandoz Group AG (SDZNY)
$19.6B
United Therapeutics (UTHR)
$17.7B
Summit Therapeutics (SMMT)
$15.4B
Neurocrine Biosciences (NBIX)
$12.7B
Shionogi (SGIOY)
$12.3B
Catalent (CTLT)
$10.9B
Madrigal Pharmaceuticals (MDGL)
$7.4B
Jazz Pharmaceuticals (JAZZ)
$6.9B
Orion OYJ (ORINY)
$6.8B
Ionis Pharmaceuticals (IONS)
$5.7B
Corcept Therapeutics (CORT)
$5.7B
Crinetics Pharmaceuticals (CRNX)
$4.7B
PTC Therapeutics (PTCT)
$3.3B
Dyne Therapeutics (DYN)
$3B
Catalyst Pharmaceuticals (CPRX)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Soleno Therapeutics (SLNO)
$2.2B
NewAmsterdam Pharma (NAMS)
$2B
Recursion Pharmaceuticals (RXRX)
$2B
Centessa Pharmaceuticals (CNTA)
$1.8B
Harrow (HROW)
$1.7B
Ocular Therapeutix (OCUL)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Xencor (XNCR)
$1.6B
Ardelyx (ARDX)
$1.5B